A Safe and Reliable Technique for CNS Delivery of AAV Vectors in the Cisterna Magna
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Global gene delivery to the CNS has therapeutic importance for the treatment of neurological disorders that affect the entire CNS. Due to direct contact with the CNS, cerebrospinal fluid (CSF) is an attractive route for CNS gene delivery. A safe and effective route to achieve global gene distribution in the CNS is needed, and administration of genes through the cisterna magna (CM) via a suboccipital puncture results in broad distribution in the brain and spinal cord. However, translation of this technique to clinical practice is challenging due to the risk of serious and potentially fatal complications in patients. Herein, we report development of a gene therapy delivery method to the CM through adaptation of an intravascular microcatheter, which can be safely navigated intrathecally under fluoroscopic guidance. We examined the safety, reproducibility, and distribution/transduction of this method in sheep using a self-complementary adeno-associated virus 9 (scAAV9)-GFP vector. This technique was used to treat two Tay-Sachs disease patients (30 months old and 7 months old) with AAV gene therapy. No adverse effects were observed during infusion or post-treatment. This delivery technique is a safe and minimally invasive alternative to direct infusion into the CM, achieving broad distribution of AAV gene transfer to the CNS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381 · cited 1×
“with the recent approval of Zolgensma to treat spinal muscular atrophy.(12) Unfortunately, exceptional transduction appears to be limited to the spinal cord.”
BackgroundIntravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456 · cited 1×
“The GFP vector, scAAV-CB-GFP, consisted of an AAV serotype 9 capsid carrying an expression cassette comprising a version of the chicken b-actin promoter, a GFP cDNA, and an artificial intron.(16) The GFP vector was produced by triple transfection as previously described and purified by cesium chloride gradient.”
MethodHinderer, C., Katz, N., Buza, E. L., Dyer, C., Goode, T., Bell, P., Richman, L. K., & Wilson, J. M. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.015 · Cited by 814 · cited 1×
“delivery for neurological disorders, because of strong transduction and expression in peripheral organs and the subsequent risk for toxicity.(13,17,18) Moreover, application of systemic delivery is limited in patients with neutralizing antibodies against the AAV capsid.”
BackgroundKordasiewicz, H. B., Stanek, L. M., Wancewicz, E. V., Mazur, C., McAlonis, M. M., Pytel, K. A., Artates, J. W., Weiss, A., Cheng, S. H., Shihabuddin, L. S., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.05.009 · Cited by 770
Davidson, B. L., Stein, C. S., Heth, J. A., Martins, I., Kotin, R. M., Derksen, T. A., Zabner, J., Ghodsi, A., & Chiorini, J. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3428 · Cited by 531
Gray, S. J., Matagne, V., Bachaboina, L., Yadav, S., Ojeda, S. R., & Samulski, R. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.72 · Cited by 501 · cited 2×
“delivery for neurological disorders, because of strong transduction and expression in peripheral organs and the subsequent risk for toxicity.(13,17,18) Moreover, application of systemic delivery is limited in patients with neutralizing antibodies against the AAV capsid.”
BackgroundMethodOsmotic Opening of the Blood–Brain Barrier: Principles, Mechanism, and Therapeutic Applications
Rapoport, S. I. (2000) · Cellular and Molecular Neurobiology · doi:10.1023/a:1007049806660 · Cited by 428
Gray, S. J., Nagabhushan Kalburgi, S., McCown, T. J., & Jude Samulski, R. (2013) · Gene Therapy · doi:10.1038/gt.2012.101 · Cited by 377 · cited 4×
“In agreement with previous studies, vector delivery solely to the cisterna magna results in robust transduction of the entire spinal cord.(21,28,29) However, our results show that motor neuron transduction in the lumbar region was reduced as compared to the cervical region.”
BackgroundResultInfluentialAdeno-Associated Virus Serotype 9 Transduction in the Central Nervous System of Nonhuman Primates
Samaranch, L., Salegio, E. A., San Sebastian, W., Kells, A. P., Foust, K. D., Bringas, J. R., Lamarre, C., Forsayeth, J., Kaspar, B. K., & Bankiewicz, K. S. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.200 · Cited by 299 · cited 1×
“28 No 2 February 2020 injection with sparse GFP expression in the liver and other peripheral tissues.(45) Serotype likely plays a role in peripheral tissue transduction, where comparison of AAV6 and AAV9 vectors after intracerebroventricular (i.”
BackgroundMeyer, K., Ferraiuolo, L., Schmelzer, L., Braun, L., McGovern, V., Likhite, S., Michels, O., Govoni, A., Fitzgerald, J., Morales, P., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.210 · Cited by 286
Cited by
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Various AAV Serotypes and Their Applications in Gene Therapy: An Overview
Issa, S. S., Shaimardanova, A. A., Solovyeva, V. V., & Rizvanov, A. A. (2023) · Cells · doi:10.3390/cells12050785 · Cited by 313
AAV gene therapy for Tay-Sachs disease
Flotte, T. R., Cataltepe, O., Puri, A., Batista, A. R., Moser, R., McKenna-Yasek, D., Douthwright, C., Gernoux, G., Blackwood, M., Mueller, C., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01664-4 · Cited by 143
Self-citationAAV vectors applied to the treatment of CNS disorders: Clinical status and challenges
Kang, L., Jin, S., Wang, J., Lv, Z., Xin, C., Tan, C., Zhao, M., Wang, L., & Liu, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.067 · Cited by 131
Rosenberg, J. B., Chen, A., De, B. P., Dyke, J. P., Ballon, D. J., Monette, S., Ricart Arbona, R. J., Kaminsky, S. M., Crystal, R. G., & Sondhi, D. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.269 · Cited by 41
Metadata
- Authors
- Taghian, T., Marosfoi, M. G., Puri, A. S., Cataltepe, O. I., King, R. M., Diffie, E. B., Maguire, A. S., Martin, D. R., Fernau, D., Batista, A. R., Kuchel, T., Christou, C., Perumal, R., Chandra, S., Gamlin, P. D., Bertrand, S. G., Flotte, T. R., McKenna-Yasek, D., Tai, P. W. L., Aronin, N., Gounis, M. J., Sena-Esteves, M., & Gray-Edwards, H. L.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 28
- Issue
- 2
- Pages
- 411-421
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2984759647
- Cited by
- 110
- References
- 14
- FWCI
- 5.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Safe and Reliable Technique for CNS Delivery of AAV Vectors in the Cisterna Magna. https://app.cochat.ai/papers/10.1016/j.ymthe.2019.11.012
- The paper
- Taghian, T., Marosfoi, M. G., Puri, A. S., Cataltepe, O. I., King, R. M., Diffie, E. B., Maguire, A. S., Martin, D. R., Fernau, D., Batista, A. R., Kuchel, T., Christou, C., Perumal, R., Chandra, S., Gamlin, P. D., Bertrand, S. G., Flotte, T. R., McKenna-Yasek, D., Tai, P. W. L., . . . Gray-Edwards, H. L. (2020). A Safe and Reliable Technique for CNS Delivery of AAV Vectors in the Cisterna Magna. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2019.11.012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.